Navigation Links
Very Small Embryonic-Like Stem Cell Mobilization Data Presented at International Society for Stem Cell Research Annual Meeting
Date:6/17/2010

ion of very small embryonic-like stem cells from the bone marrow to peripheral blood, will be presented in a poster session on June 17.

The poster is entitled "Mobilization and Isolation of Human Very Small Embryonic-Like Stem Cells (VSELs) from Peripheral Blood". Authors of the abstract included:

Dr. Mariusz Ratajczak, M.D., Ph.D., Director of the Stem Cell Biology Program at University of Louisville, which partners with NeoStem to develop technologies, based on NeoStem's exclusive license, to identify and isolate rare adult stem cells called very small embryonic-like stem cells;

Dr. Wayne A. Marasco, M.D., Ph.D., Associate Professor at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School, and Chairman of NeoStem's Scientific Advisory Board;

Denis O. Rodgerson, Ph.D., MSC, Director of Stem Cell Science at NeoStem.

Satish Medicetty, Ph.D., formerly Director of Stem Cell Research & Laboratory Operations at NeoStem.

The abstract shows that very small embryonic-like stem cells, normally rare in peripheral blood, can be released in greater numbers from the bone marrow by using an FDA approved drug called G-CSF. They can then be collected by a process called apheresis, a process used as standard-of-care in blood donations. The authors postulate that G-CSF mobilization could become a novel strategy to obtain human pluripotent stem cells, which are stem cells that have the potential to regenerate all the cell types of the body. In this poster, the authors have presented data taken from 28 human donors that demonstrate the significant
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
2. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
3. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
4. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
5. New technique producing small things in large quantities
6. Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis
7. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
8. Small Bone Innovations Introduces New Distal Radius Plating System to Repair Complex Fractures
9. Cepheid to Present at William Blair Small-Cap Growth Stock Conference
10. Government Expands Trial With IMVAMUNE(R) Smallpox Vaccine in Persons With Atopic Dermatitis/Eczema
11. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 2014 Research and Markets ... N-acetylcysteine Industry Report 2014" report to their ... Report 2014 is a professional and in-depth study ... industry. The report provides a basic ... and industry chain structure. The N-acetylcysteine market analysis ...
(Date:9/18/2014)... 18, 2014 Leatherwood Plastics has ... material, to stay competitive in the semiconductor, clean ... materials ultimately impact product quality and productivity, according ... , Established in 1980 in Lewisville, TX, ... fabricators have left the business. Much of Leatherwood’s ...
(Date:9/18/2014)... Ky. , Sept. 18, 2014  Neogen Corporation ... has entered into a strategic agreement with Merck Animal ... Program. The Igenity Dairy Heifer Program ... essential information on the genetic potential of replacement dairy ... a calf is born, and is an excellent tool ...
(Date:9/18/2014)... 18, 2014   Sigma-Aldrich Corporation (Nasdaq: ... entered into a new gene editing partnership with ... Core. Under the partnership, Sigma-Aldrich will provide the ... consultation, and dedicated gene editing bioinformaticians. ... research at the U-M Medical School. One initiative ...
Breaking Biology Technology:Global N-acetylcysteine Industry Report 2014 2Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2Merck Animal Health to market Neogen's dairy genomic program 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4
... November 14, 2008 at 9:00 a.m. Eastern ... ... Inc. (Nasdaq: ALSE ) today reports operational and,financial results for the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO ), "We are encouraged by the ...
... Alternext US: PIP), a biodefense company developing medical,countermeasures ... operational results for the third quarter and nine ... quarter of 2008, PharmAthene recognized revenues of $10.7,million ... of 2007. For the nine,months ended September 30, ...
... Choice, Based on Its Comprehensive,Service Portfolio, MOUNTAIN ... recent,analysis of the pharmaceutical contract manufacturing market, Frost ... the 2008 North,American Frost & Sullivan Customer Service ... in Healthcare Innovation Awards Banquet held in San,Antonio, ...
Cached Biology Technology:Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 2Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 3Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 4Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 5Pharmathene Reports Third Quarter 2008 Financial and Operational Results 2Pharmathene Reports Third Quarter 2008 Financial and Operational Results 3Pharmathene Reports Third Quarter 2008 Financial and Operational Results 4Pharmathene Reports Third Quarter 2008 Financial and Operational Results 5Pharmathene Reports Third Quarter 2008 Financial and Operational Results 6Pharmathene Reports Third Quarter 2008 Financial and Operational Results 7Frost & Sullivan Awards Baxter's BioPharma Solutions Business the 2008 North American Customer Service Leadership of the Year Award 2Frost & Sullivan Awards Baxter's BioPharma Solutions Business the 2008 North American Customer Service Leadership of the Year Award 3
(Date:9/18/2014)... research into the Crimean-Congo hemorrhagic fever virus (CCHFV), a ... humans similar to that caused by Ebolavirus, has identified ... has the potential to lead to novel targets for ... research, reported in a paper published today in the ... at the Texas Biomedical Research Institute and their colleagues, ...
(Date:9/18/2014)... prompts millions of Americans to undertake jaunts into the countryside ... little longer within a century, according to new research. , ... of the United States as summer temperatures linger later into ... Global Ecology and Biogeography . For instance, the paper birch ... of New Hampshire could change color one to three ...
(Date:9/18/2014)... Americans across racial and ethnic groups describe losing ... their day-to-day life, more so than other conditions ... (57% of African-Americans, 49% of non-Hispanic whites, 43% ... which disease or ailment is the worst that ... African-Americans followed by AIDS/HIV. Hispanics and Asians ...
Breaking Biology News(10 mins):Research milestone in CCHF virus could help identify new treatments 2Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3
... by Vanderbilt,s Roger Cone, Ph.D., have discovered a new member ... and the regulation of body weight. The gene is the ... been identified previously in humans. One helps determine skin and ... in obesity and diabetes. The new gene, called agrp2, has ...
... -- Curcumin, a chemical that gives curry its zing, ... an advanced form of a condition known as fatty ... Curcurmin is contained in turmeric, a plant used by ... years. SLU,s recent study highlights its potential in countering ...
... London today signed an official agreement to jointly establish ... by Prime Minister Lee Hsien Loong at the National ... for the school is "Imperial College London-Nanyang Technological University ... ICNMS will be positioned to meet Singapore,s healthcare demands ...
Cached Biology News:Newly discovered gene enables fish to 'disappear' 2Spice in curry could prevent liver damage 2Imperial and NTU's new medical school aspires to be global health care role model 2Imperial and NTU's new medical school aspires to be global health care role model 3Imperial and NTU's new medical school aspires to be global health care role model 4
...
... Kit Components , 25 g Blocking Reagent , ... 10 ml T7 Elution Buffer , 0.2 ml BL21 ... 0.2 ml BLT5615 glycerol stock , 1010 pfu ... Control Lysate , 50 l S-protein HRP Conjugate , ...
Mouse monoclonal [7A6] to NFAT2 ( Abpromise for all tested applications). entrezGeneID: 4772 SwissProtID: O95644...
... are designed for ultra-sensitive detection of ... PVDF membranes. Since all necessary reagents ... antibodies), the WesternBreeze Kits save you ... and getting your final results. Solutions ...
Biology Products: